TransDerm Inks Research Deal with RXi, Gets Grant to Explore Delivery Technologies | GenomeWeb

By Doug Macron

TransDerm, which is developing an siRNA-based treatment for a rare skin disorder, has begun evaluating a variety of different drug-delivery technologies that it hopes will improve the performance of the drug that was observed in a recent phase Ib study.

This week, the company announced that it has formed a research alliance with RXi Pharmaceuticals to evaluate RXi's proprietary RNAi compounds, including its so-called self-delivering rxRNAs, in dermatology models.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.